Observational studyBreast cancer research and treatment2026

Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study.

Olivia Lavigne et al.PubMed ↗Publisher ↗

No numbers read from the abstract.